Biopharmaceutical company
Appears in 1 story
Sponsor of volixibat; targeting NDA filing in 2H 2026
For the roughly 30,000 Americans living with primary sclerosing cholangitis (PSC), the U.S. Food and Drug Administration has never approved a single drug. On May 4, 2026, that drought moved closer to ending: Mirum Pharmaceuticals reported that its experimental pill volixibat hit the primary endpoint of its Phase 2b VISTAS trial, cutting the relentless itch that defines the disease by a wide margin over placebo.
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
